Contrasting INC Research Holdings (INCR) and Arena Pharmaceuticals (ARNA)
Arena Pharmaceuticals (NASDAQ: ARNA) and INC Research Holdings (NASDAQ:INCR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.
Insider & Institutional Ownership
99.8% of INC Research Holdings shares are held by institutional investors. 1.9% of Arena Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of INC Research Holdings shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Arena Pharmaceuticals and INC Research Holdings’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|INC Research Holdings||5.69%||40.69%||9.87%|
Earnings and Valuation
This table compares Arena Pharmaceuticals and INC Research Holdings’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Arena Pharmaceuticals||$117.73 million||6.84||$16.71 million||($0.57)||-36.02|
|INC Research Holdings||$1.03 billion||2.95||$226.74 million||$1.61||34.78|
INC Research Holdings has higher revenue and earnings than Arena Pharmaceuticals. Arena Pharmaceuticals is trading at a lower price-to-earnings ratio than INC Research Holdings, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and price targets for Arena Pharmaceuticals and INC Research Holdings, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|INC Research Holdings||0||4||4||0||2.50|
Arena Pharmaceuticals presently has a consensus price target of $38.83, indicating a potential upside of 89.15%. INC Research Holdings has a consensus price target of $64.58, indicating a potential upside of 15.33%. Given Arena Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Arena Pharmaceuticals is more favorable than INC Research Holdings.
Risk and Volatility
Arena Pharmaceuticals has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, INC Research Holdings has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.
INC Research Holdings beats Arena Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Arena Pharmaceuticals
Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company’s drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company’s drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company’s programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).
About INC Research Holdings
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers a range of clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
Receive News & Stock Ratings for Arena Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.